Related Experiment Video
Updated: Sep 19, 2025

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
Severe transient neonatal hyperinsulinism: First Peruvian case series
Manuel André Virú-Loza1, Francesca Bermudez-Paredes2, Isabel Milagros Arauco-Carhuas2
1Unidad de Revisiones Sistemáticas y Meta-análisis, Vicerrectorado de Investigación, Universidad San Ignacio de Loyola, Lima, Peru.
Insights
Congenital hyperinsulinism causes severe hypoglycemia in children. Diazoxide effectively treated Peruvian infants with transient hyperinsulinism, showing manageable side effects.
Area of Science:
- Pediatric Endocrinology
- Neonatal Medicine
- Pharmacology
Background:
- Congenital hyperinsulinism (CHI) is a leading cause of pediatric hypoglycemia, risking significant brain damage.
- Transient forms of CHI, including those from perinatal stress, are common.
- Diazoxide is the established first-line treatment for CHI.
Observation:
- Reports on diazoxide use in Peruvian pediatric patients with hyperinsulinism are limited.
- This study presents the first Peruvian case series of severe transient neonatal hyperinsulinism.
- Patients were treated with diazoxide, a crucial medication for managing hyperinsulinism.
Findings:
- The case series demonstrated a good response to diazoxide treatment in severe transient neonatal hyperinsulinism.
- Adverse effects associated with diazoxide were manageable.
- This highlights diazoxide's efficacy in the Peruvian pediatric population.
Implications:
- Diazoxide is an essential medication for treating congenital hyperinsulinism.
- Inclusion of diazoxide in Peru's national formulary is recommended for timely access.
- This case series supports broader implementation of diazoxide therapy for pediatric hyperinsulinism in Peru.
Abstract:
Congenital hyperinsulinism is characterized by dysregulated insulin secretion and is the most common and severe cause of persistent hypoglycemia in pediatrics. Brain damage rates can be as high as 50% due to inadequate treatment. Transient congenital hyperinsulinism is more frequent than permanent congenital hyperinsulinism. Acquired hyperinsulinism due to perinatal stress is often transient, too. Diazoxide is the first-line therapy. However, in Peru, reports about pediatric patients with hyperinsulinism treated with diazoxide are scarce. Our article describes the first Peruvian case series of severe transient neonatal hyperinsulinism treated with diazoxide, with good response and manageable adverse effects. Diazoxide should be included in the Single National Pharmaceutical Request Form for Essential Medicines of Peru to expedite the use of a medication as essential as this one.
Related Concept Videos
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes Mellitus: Type 2 and Gestational
Hypoglycemia and Glucagon
Inborn Errors of Metabolism
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...

